Gilberto Lopes, Chief of the Division of Medical Oncology at the Sylvester Comprehensive Cancer Center, shared a post on X:
“GLP-1 RAs + Standard of Care Can Reduce Mortality Risk in HR-Positive, HER2-Negative Metastatic Breast Cancer.”
Harold J. Burstein, Breast Cancer Specialist and Professor at Dana-Farber Cancer Institute and at Harvard Medical School, shared a post by Gilberto Lopes, adding:
“One suspects that the issue here is that GLP1 agonists will help people’s overall survival, regardless, as to whether they have cancer. One is treating obesity, sleep apnea, diabetes, etc which probably make a difference for patients with cancer.”
Other articles featuring Dr. Lopes on OncoDaily.